| William A Parker Jr, MD | |
|
2359 Lakeview Drive, Allergy & Asthma Associates, Beavercreek, OH 45431-3695 | |
| (937) 431-0721 | |
| (937) 431-5419 |
| Full Name | William A Parker Jr |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 43 Years |
| Location | 2359 Lakeview Drive, Beavercreek, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780665430 | NPI | - | NPPES |
| 0857603 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 35-05-8156-P (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psf Pllc | 1557265543 | 98 |
News Archive
According to new research by the National Health Service (NHS), 60 per cent of smokers light up and smoke without asking for permission, despite the fact that most non-smokers mind if other people are smoking nearby.
A study published in the July 23 issue of Cell identifies the mechanism used by several types of common, virulent microbes to infect plants and cause devastating blights. Microbes using this infection mechanism include fungi that are currently causing wheat rust epidemics in Africa and Asia, and a class of parasitic algae, called oomycetes, that resulted in the Irish potato blight of the 19th Century. These microbes remain an agricultural scourge today.
The U.S. government's Medicare program has ordered three health insurers Universal American Corp. (UAM), Health Net Inc. (HNT) and Arcadian Health to stop marketing to and enrolling new members in their Medicare Advantage health and prescription-drug plans, saying the companies violated regulations.
Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.
› Verified 6 days ago
| Entity Name | Psf Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881785947 PECOS PAC ID: 1557265543 Enrollment ID: O20180910001695 |
News Archive
According to new research by the National Health Service (NHS), 60 per cent of smokers light up and smoke without asking for permission, despite the fact that most non-smokers mind if other people are smoking nearby.
A study published in the July 23 issue of Cell identifies the mechanism used by several types of common, virulent microbes to infect plants and cause devastating blights. Microbes using this infection mechanism include fungi that are currently causing wheat rust epidemics in Africa and Asia, and a class of parasitic algae, called oomycetes, that resulted in the Irish potato blight of the 19th Century. These microbes remain an agricultural scourge today.
The U.S. government's Medicare program has ordered three health insurers Universal American Corp. (UAM), Health Net Inc. (HNT) and Arcadian Health to stop marketing to and enrolling new members in their Medicare Advantage health and prescription-drug plans, saying the companies violated regulations.
Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William A Parker Jr, MD 9800 Shelbyville Rd Ste 220, Louisville, KY 40223-2992 Ph: (502) 429-8585 | William A Parker Jr, MD 2359 Lakeview Drive, Allergy & Asthma Associates, Beavercreek, OH 45431-3695 Ph: (937) 431-0721 |
News Archive
According to new research by the National Health Service (NHS), 60 per cent of smokers light up and smoke without asking for permission, despite the fact that most non-smokers mind if other people are smoking nearby.
A study published in the July 23 issue of Cell identifies the mechanism used by several types of common, virulent microbes to infect plants and cause devastating blights. Microbes using this infection mechanism include fungi that are currently causing wheat rust epidemics in Africa and Asia, and a class of parasitic algae, called oomycetes, that resulted in the Irish potato blight of the 19th Century. These microbes remain an agricultural scourge today.
The U.S. government's Medicare program has ordered three health insurers Universal American Corp. (UAM), Health Net Inc. (HNT) and Arcadian Health to stop marketing to and enrolling new members in their Medicare Advantage health and prescription-drug plans, saying the companies violated regulations.
Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.
› Verified 6 days ago
Mrs. Dena Denise Bell, CFNP Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2359 Lakeview Dr, Beavercreek, OH 45431 Phone: 937-431-0721 Fax: 937-431-5419 |